See more : PPK Group Limited (PLPKF) Income Statement Analysis – Financial Results
Complete financial analysis of Abbisko Cayman Limited (2256.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbisko Cayman Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Jackson Acquisition Company (RJAC-WT) Income Statement Analysis – Financial Results
- ikeGPS Group Limited (IKE.NZ) Income Statement Analysis – Financial Results
- In Win Development Inc. (6117.TW) Income Statement Analysis – Financial Results
- SPRIX, Ltd. (7030.T) Income Statement Analysis – Financial Results
- TWi Biotechnology, Inc. (6610.TWO) Income Statement Analysis – Financial Results
Abbisko Cayman Limited (2256.HK)
About Abbisko Cayman Limited
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 19.06M | 0.00 | 22.68M | 0.00 | 3.84M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 19.06M | 0.00 | 22.68M | 0.00 | 3.84M |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% |
| Research & Development | 433.74M | 378.75M | 226.13M | 132.66M | 81.46M |
| General & Administrative | 35.61M | 29.82M | 54.84M | 9.11M | 12.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.61M | 29.82M | 54.84M | 9.11M | 12.06M |
| Other Expenses | -450.29M | 78.08M | 55.86M | 4.76M | 5.99M |
| Operating Expenses | 19.06M | 486.64M | 336.82M | 146.53M | 99.51M |
| Cost & Expenses | 530.14M | 486.64M | 336.82M | 146.53M | 99.51M |
| Interest Income | 65.49M | 35.02M | 16.94M | 11.27M | 7.86M |
| Interest Expense | 2.17M | 2.69M | 959.00K | 338.00K | 523.00K |
| Depreciation & Amortization | 18.42M | 4.57M | 11.89M | 3.62M | 3.11M |
| EBITDA | -410.99M | -492.62M | -1.80B | -696.98M | -96.40M |
| EBITDA Ratio | -2,156.30% | 0.00% | -7,949.25% | 0.00% | -3,282.23% |
| Operating Income | -511.08M | -492.92M | -1.81B | -706.47M | -134.13M |
| Operating Income Ratio | -2,681.41% | 0.00% | -8,001.65% | 0.00% | -3,495.78% |
| Total Other Income/Expenses | 79.49M | -2.69M | -1.50B | -552.81M | -34.40M |
| Income Before Tax | -431.58M | -495.61M | -1.81B | -706.64M | -133.91M |
| Income Before Tax Ratio | -2,264.34% | 0.00% | -7,979.87% | 0.00% | -3,490.02% |
| Income Tax Expense | 0.00 | 2.69M | -4.94M | 172.00K | -221.00K |
| Net Income | -431.58M | -498.29M | -1.81B | -706.81M | -133.69M |
| Net Income Ratio | -2,264.34% | 0.00% | -7,958.08% | 0.00% | -3,484.26% |
| EPS | -0.67 | -0.80 | -7.68 | -1.02 | -0.19 |
| EPS Diluted | -0.67 | -0.80 | -7.68 | -1.01 | -0.19 |
| Weighted Avg Shares Out | 647.23M | 620.68M | 234.88M | 695.13M | 702.47M |
| Weighted Avg Shares Out (Dil) | 647.23M | 620.68M | 234.88M | 702.47M | 702.47M |
Source: https://incomestatements.info
Category: Stock Reports